|
May 2002 (v02-n05) |
|
- Main Story - pgs. 1-15 Id Biomedical (NASDAQ:IDBE)
- NIBM Model Portfolio Updates - pgs. 16-23
- Macro Market Commentary - pgs. 24-25
- NIBM Model Portfolio - pg. 26
|
 |
|
| This month's Main Story is on Id Biomedical.
Id is a leading developer of preventative vaccines. FluINsure is the company's nasal
influenza vaccine in Phase II trials. StreptAvax is the company's revolutionary strep
vaccine, also in phase II trials. The company's most promising preclinical product could cure
allergies with a simple nasal spray. |
 |
|
| The following is an outline of this issue of
the NIBM Newsletter. |
Subscriber direct access |
|
| |
|
|
- Main Story - Id Biomedical
- Introduction
- Table: Basic Facts
- Investment case
- Disclosure
FluINsure
- Table: Assorted influenza facts - Worldwide and US data
- Flu facts
- Preventing the flu
- IgG versus IgA immunity
- The product
- FluINsure clinical trials
- Table: FluINsure Phase I trivalent
- The FluMist experience
- Table: FluMist FDA response
- FluINsure clinical pathway
- Competitive profiles
- FluINsure vs. FluMist
- FluINsure vs. injected vaccines
- FluINsure vs. Nasalflu
- Operations and Reimbursement
- Market Potential
StreptAvax
- M proteins and GrAS
- The vacine
- Clinical trials
- Operations, reimbursement, and market
Pipeline
- Allergy cures
- RSV, e-Coli, and tuberculosis
- Cancer
Cycling Probe Technology
Operations/Management
Table: Upcoming milestones
What Can Go Wrong
- NIBM Model Portfolio and Updates
- AltaRex
- Table: Berek/Ehlen study
- Table: Dosage study
- Table: Further results
- Coming events (2002)
- Titan Pharmaceuticals
- Indevus
- Zoloft versus Pagoclone
- Pregabalin versus Pagoclone
- Genta
- Dendreon
- Provenge poster
- Table: Phase
I, II, & III patient population comparison
- Mylovenge
- Table: Mayo
study data
- Targeted Genetics
- Titan Pharmaceuticals
Macro Market Commentary |
|
|
| |
|
|
 |
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
